RSPO2 and cancer: In the p.Pro103Ala variant, which was designed and functionally tested by a previous study on cancer aspects to decrease the Wnt signaling,38 these interactions are lost, resulting in weaker RSPO2 binding (Figure 4E), and we also observed a decreased Wnt signaling in our functional assay like in the p.Leu104Pro variant.